About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study on the Applicability of CCR Criteria in Rectal Cancer

NCT06794099·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Peking University Cancer Hospital & Institute

Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. histopathologically confirmed adenocarcinoma;
2. pMMR/MSS tumors;
3. clinical staging of T3-T4 or any lymph node-positive T (N+);
4. no evidence of distant metastasis based on radiological examinations;
5. treatment with long-course chemoradiotherapy (LCRT) with or without immune checkpoint inhibitors (ICI);
6. post-neoadjuvant therapy evaluation with endoscopy and pelvic MRI.

You may not be if

1. Presence of other active malignancies;
2. Having severe comorbidities, such as heart failure, severe hepatic or renal insufficiency, etc;
3. Lack of imaging and endoscopic examinations;
4. Treatment plan does not meet the study requirements.

The record

StatusCompleted

PhaseNo phase

Taking part177

StartedJan 2019

UpdatedJan 27, 2025

Conditions

PMMR/MSS Adenocarcinoma of the Colon or Rectum Neoadjuvant Chemoradiotherapy Immunotherapy Complete Response

Where1

Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China

Clareo Health | Study on the Applicability of CCR Criteria in Rectal Cancer